The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Also included is breaking research, clinical, regulatory and business development news on coronaviruses reaching back to 1991. Featured topics: vaccines and diagnostics in development, the science underpinning the virus, comparison to previous outbreaks such as Severe acute respiratory syndrome (SARS) and Middle Eastern respiratory syndrome coronavirus (MERS-CoV), global regulatory factors and the business news underpinning the research including development collaborations and investment trends.
HONG KONG – Fujifilm Holdings Corp. stock (TYO:4901) jumped 8.8% to ¥5,890 (US$53.48) on Feb. 25, as Japan considers using Avigan (favipiravir), an anti-influenza medication developed by the company’s Toyama Chemical Co. Ltd., to treat COVID-19. The share price ended the day at ¥5,567, for a gain of 2.83%.
BEIJING – Multiple China-based clinical trials have been put on hold as the country concentrates on its fight against COVID-19. To curb the spread of the novel coronavirus that has infected over 72,000 people and killed nearly 2,000, China has imposed travel and transport restrictions, making trips difficult or even impossible for patients and physicians.
Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief, including: Amarillo, Aptorum, Cipla, CNS Pharma, Codagenix, Cytodyn, Daewoong, Dr. Reddy’s, J&J, Jianjin University Haihe Hospital, Luye, M8 Pharma, Monash University, Recce, Synergy, Vir, Wockhardt, WPD Pharma, Xiamen Weiyang.
Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief, including: Alterity, Athenex, Aurigene Discovery, Beijing CC-Pharming, Bill & Melinda Gates Foundation, Bridge Biotherapeutics, China Grand, Clover, Curis, Ibio, Oncosec, Porton Pharma Solutions, Q Biomed, Recce.
HONG KONG – In another example that communication is proving as difficult as containment in the current coronavirus outbreak, China’s state media reported, to increasing skepticism, that a traditional Chinese medicine (TCM) oral liquid could inhibit the new coronavirus.